ScreenerHero

CING Cingulate Inc.

NAS · US · Healthcare · Biotechnology · cingulate.com
4.870USD-0.41%Mkt Cap: 70.82M $P/E: —

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United Sta…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap70.82M USD
Enterprise Value49.00M USD
Revenue (TTM)—
Gross Profit-8.52M USD
Net Income (TTM)-22.45M USD
Revenue/Share—
Last Price4.870 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.56
PEG—
EV/EBITDA-2.00
EV/Revenue—
P/S—
P/B2.90
EPS (TTM)-3.57
EPS (Forward)-0.88
52W Range
3.16020% of range11.89
52W High11.89 USD
52W Low3.160 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-894.81%
ROA-148.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.25M USD
CapEx (TTM)162.14K USD
FCF Margin—
FCF Yield-18.13%
Net Debt-22.11M USD
Net Debt/EBITDA0.90
Balance Sheet
Debt/Equity3.50
Current Ratio3.50
Quick Ratio3.30
Book Value/Sh1.69 USD
Cash/Share1.95 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateAug 9, 2024
Analyst Consensus
Rating—
Target (Mean)21.20 USD
Upside (mean)+335.3%
Target Range8.000 USD – 44.00 USD
8.000+335.3% to mean44.00
# Analysts5
Ownership
Shares Out.14.54M
Float14.20M
Insiders28.29%
Institutions12.59%
Short Interest
Short Ratio9.2d
Short % Float11.23%
Short % Out.8.05%
Shares Short1.17M
Short (prev mo.)1.20M
Technical
SMA 505.090 (-4.3%)
SMA 2005.402 (-9.8%)
Beta-0.88
S&P 52W Chg16.45%
Avg Vol (30d)107.87K
Avg Vol (10d)97.18K
Technical Indicators
RSI (14)45.3
MACD-0.0799
MACD Signal-0.0571
MACD Hist.-0.0228
BB Upper5.349 USD
BB Middle5.003 USD
BB Lower4.656 USD
BB Width13.85%
ATR (14)0.2645 USD
Vol Ratio (20d)1.25x